ASCO GU25泌尿肿瘤盛会来袭，精选摘要标题提前揭秘！3位中国学者研究入选

2025年美国临床肿瘤学会泌尿生殖肿瘤研讨会(ASCO GU25）将于2月13-15号在美国旧金山举办。近期，ASCO GU官网公布了摘要标题。

CCMTV泌尿频道整理了入选全体大会、口头报告、快速口头报告专题的摘要标题，按照中国学者研究优先、LBA优先的规则排序，以飨读者。

Nectin-4靶向抗体偶联药物SHR-A2102治疗晚期或转移性尿路上皮癌患者的I期研究。

Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.

报告人：唐碧霞

单位：北京大学肿瘤医院

WOLVERINE：基于X-MET合作组织的随机试验个体患者数据（IPD）的全球寡转移性前列腺癌（omPC）荟萃分析

World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.

报告人：Chad Tang

单位：The University of Texas MD Anderson Cancer Center

在177Lu-PSMA-617的PSMAfore研究中，基线与治疗期间循环肿瘤DNA（ctDNA）比例与转移性去势抵抗性前列腺癌（mCRPC）患者临床结局的相关性。

Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617

报告人：Johann De Bono

单位：The Royal Marsden NHS Foundation Trust

在ENZA-p（ANZUP 1901）试验中，针对高危、转移性、去势抵抗性前列腺癌患者，比较[¹⁷⁷Lu]Lu-PSMA-617联合恩扎卢胺vs恩扎卢胺单药治疗患者的总生存期和生活质量。

Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).

报告人：Louise Emmett

单位：St Vincent's Hospita

评估循环肾损伤标志物-1（KIM-1）作为晚期肾细胞癌（aRCC）预后和预测生物标志物的价值：CheckMate 214试验的事后分析

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

报告人：Wenxin Xu

单位：Dana-Farber Cancer Institute

HER2阳性肌层浸润性膀胱癌（MIBC）患者接受维迪西妥单抗联合围手术期特瑞普利单抗的新辅助治疗：来自II期RC48-C017试验的最新疗效和安全性结果。

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.

报告人：盛锡楠

单位：北京大学肿瘤医院

在III期TALAPRO-2试验中，未筛选的转移性去势抵抗性前列腺癌（mCRPC）患者接受他拉唑帕利（TALA）+恩扎卢胺（ENZA）作为一线治疗的最终总生存期（OS）。

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

报告人：Neeraj Agarwal

单位：Huntsman Cancer Institute at the University of Utah

哪些转移性激素敏感性前列腺癌（mHSPC）患者从雄激素受体通路抑制剂（ARPIs）中获益更多？STOPCAP个体参与者数据（IPD）荟萃分析。

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

报告人：David Fisher

单位：MRC Clinical Trials Unit at UCL

前列腺癌放疗剂量反应的基因特征预测指标：PORTOS在III期试验中的验证。

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

报告人：Shuang Zhao

单位：Department of Human Oncology, University of Wisconsin-Madison

高危前列腺癌（HR-PCa）中的根治性前列腺切除术（RP）与放射治疗（RT）：基于两项III期随机试验（RCTs）个体患者数据（IPD）的模拟随机对照比较。

Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).

报告人：Soumyajit Roy

单位：Rush University Medical Center

卡博替尼（C）联合纳武利尤单抗（N）和伊匹木单抗（I）治疗初治晚期肾细胞癌（aRCC）：COSMIC-313研究的最终结果。

Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.

报告人：Laurence Albiges

单位：Institut Gustave Roussy, Université Paris Saclay

纳武利尤单抗联合卡博替尼（N+C）对比舒尼替尼（S）治疗初治晚期肾细胞癌（aRCC）：CheckMate 9ER试验的最终随访结果。

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

报告人：Robert Motzer

单位：Memorial Sloan Kettering Cancer Center

KEYMAKER-U03 Substudy 03B：帕博利珠单抗（pembro）与靶向治疗联合用于晚期透明细胞肾细胞癌（ccRCC）的研究。

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).

报告人：Laurence Albiges

单位：Gustave Roussy, Paris-Saclay University

前瞻性COTRIMS试验（科隆转移性精原细胞瘤腹膜后淋巴结清扫术试验）的最终结果。

Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.

报告人：Axel Heidenreich

单位：Department of Urology, University Hospital of Cologne

纳武利尤单抗（NIVO）辅助疗法对比安慰剂（PBO）用于高危肌层浸润性尿路上皮癌（MIUC）：来自CheckMate 274研究的额外疗效结果，包括肌层浸润性膀胱癌（MIBC）患者的总生存期（OS）。

Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

报告人：Matthew Milowsky

单位：University of North Carolina School of Medicine

来自NIAGARA研究的额外疗效和安全性结果，以及对病理完全缓解（pCR）对长期结局影响的探索性分析。

Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.

报告人：Matthew Galsky

单位：Icahn School of Medicine at Mount Sinai

新辅助免疫治疗药物度伐利尤单抗（MEDI 4736）联合新辅助化疗（吉西他滨/顺铂或卡铂）在治疗可切除高危上尿路尿路上皮癌患者中的安全性和有效性。

Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.

报告人：Nadine Houede

单位：Oncology Department, Montpellier University

仑伐替尼联合特瑞普利单抗作为一线治疗晚期延胡索酸水合酶缺乏型肾细胞癌的单中心、单臂、II期研究

Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.

报告人：孔文

单位：上海交通大学医学院附属仁济医院

Mevrometostat (PF-06821497)联合恩扎卢胺治疗转移性去势抵抗性前列腺癌（mCRPC）患者的随机剂量扩展研究。

Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.

报告人：Michael Schweizer

单位：Fred Hutchinson Cancer Center

EPIC-A：局部晚期或转移性阴茎癌患者接受西米普利单抗联合标准化疗序贯西米普利单抗维持治疗的II期试验。

EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.

报告人：Amit Bahl

单位：University Hospitals Bristol and Weston NHS Foundation Trust

经皮雌二醇（tE2）贴片作为雄激素剥夺疗法（ADT）：在转移性（M1）前列腺癌中联合雄激素受体通路抑制剂（ARPIs）的有效性和安全性——来自STAMPEDE试验平台的随机对照研究。

Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.

报告人：Nicholas James

单位：The Royal Marsden Hospital NHS Foundation Trust

在寡转移性激素抵抗性前列腺癌中，除标准全身治疗外增加转移灶导向治疗的随机II期试验（GROUQ-PCS 9）。

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).

报告人：Tamim Niazi

单位：McGill University

雄激素剥夺治疗后睾酮水平恢复对高危前列腺癌患者总生存期的影响：一项III期试验的长期数据。

Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.

报告人：Abdenour Nabid

单位：Centre Hospitalier Universitaire de Sherbrooke

肠道健康与前列腺癌：一种富含特定植物化学成分的食品胶囊联合或不联合益生菌/益生元混合物对症状及疾病进展的影响——一项随机、双盲、安慰剂对照试验。

Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial.

报告人：Robert Thomas

单位：Addenbrooke's Hospital

针对接受主动监测的前列腺癌男性患者的高omega-3、低omega-6饮食联合鱼油干预：CAPFISH-3随机临床试验

A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial.

报告人：William Aronson

单位：VA Greater Los Angeles Healthcare System

经治的透明细胞肾细胞癌（ccRCC）患者接受

Casdatifan单药治疗的疗效、安全性和多剂量亚组分析：来自I期开放标签研究ARC-20的数据。

Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.

报告人：Toni Choueiri

单位：Dana-Farber Cancer Institute

肾细胞癌的组织学特征与预后中的种族差异：来自法国肾癌研究网络（UroCCR-191）的见解

Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).

报告人：Xiaofan Lu

单位：Institut de génétique, biologie moléculaire et cellulaire (IGBMC)

MET驱动的晚期乳头状肾细胞癌的最终总生存期和新ctDNA分析（CALYPSO研究）

Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).

报告人：Francesca Jackson-Spence

单位：Barts Cancer Centre

LY3866288（LOXO-435），一种强效、高度异构体选择性FGFR3抑制剂（FGFR3i）在FGFR3改变的晚期实体瘤患者中的首次人体1期研究：FORAGER-1的初步结果。

A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.

报告人：Gopa Iyer

单位：Department of Medicine, Memorial Sloan Kettering Cancer Center

德曲妥珠单抗（Dato-DXd）在局部晚期/转移性尿路上皮癌中的应用：I期TROPION-PanTumor01研究的最新结果。

Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.

报告人：Funda Meric-Bernstam

单位：The University of Texas MD Anderson Cancer Center

EV-302：III期全球研究enfortumab vedotin联合帕博利珠单抗（EV+P）对比化疗治疗初治局部晚期或转移性尿路上皮癌（la/mUC）的更新分析。

EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

报告人：Thomas Powles

单位：Queen Mary University of London, St. Bartholomew's Hospital

年轻发病膀胱癌（YOUC）患者中的临床进展期尿路上皮膀胱癌（CAUBC）：一项基因组学研究。

Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.

报告人：Alina Basnet

单位：SUNY Upstate Medical University

针对BCG无应答的非肌层浸润性膀胱癌患者的度伐利尤单抗联合膀胱内灌注吉西他滨和多西他赛的I/II期试验（HCRN GU16-243：ADAPT-BLADDER队列4）

A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).

报告人：Noah Hahn

单位：Johns Hopkins University School of Medicine

肌肉浸润性膀胱癌新辅助化疗免疫治疗后的风险适应性治疗（RETAIN-2）的2期试验。

A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).

报告人：Pooja Ghatalia

单位：Fox Chase Cancer Center